Kadimastem, Merck KGaA deal

Merck's Merck Serono division partnered with Kadimastem to use the Israeli company's drug-screening technology to discover oral therapies for multiple sclerosis (MS). Under the five-year deal, Kadimastem will use its pluripotent stem cell technology to screen for compounds from Merck that stimulate myelin repair. ...